United Kingdom-based GW Pharmaceuticals posted marginal revenue growth in the second quarter over the previous quarter, citing challenges stemming from the COVID-19 pandemic. GW reported revenue of $121.3 million for the quarter ended June 30 – about the same as the previous period. GW’s quarterly net loss rose slightly to $8.8 million. By product, Epidiolex […]
Epidiolex maker GW Pharma turns in flat second quarter on pandemic impact is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs
Be First to Comment